Printer Friendly

BERGEN BRUNSWIG REPORTS FIRST QUARTER RESULTS

 ORANGE, Calif., Dec. 16 /PRNewswire/ -- Bergen Brunswig Corp. (AMEX: BBC) today reported results for the first fiscal quarter ended Nov. 30, 1992.
 Net sales and other revenues for the quarter increased 39 percent to a record $1.60 billion from $1.15 billion for the comparable quarter last year. A portion of the increase in net sales is attributable to the acquisitions of Durr-Fillauer Medical Inc. in September 1992, and of substantially all of the drug distribution business of Owens & Minor Inc. in February 1992.
 Although Bergen Brunswig previously indicated a decision to seek a buyer for Durr's medical supply business, the offers it received for that business were unacceptable. Having assessed the contribution which Durr's medical business has already made and its potential for future contributions to the Durr operations, Bergen Brunswig has resolved to retain and to develop that business.
 Net earnings for the quarter were $11.9 million, an increase of 34 percent compared to $8.9 million in the prior year's quarter. Fully diluted earnings per share increased 45 percent to $0.32 compared to $0.22 a year ago. The current period net earnings of $11.9 million, all from continuing operations, compares to $6.6 million last year. Earnings from discontinued operations, net of taxes on income, of $2.3 million a year ago relate to Commtron Corp., a video distribution subsidiary sold in June 1992. Last year's first quarter earnings included a $5.1 million after tax charge for probable losses incurred in connection with credit extended to certain customers.
 Robert E. Martini, chairman and chief executive officer of Bergen Brunswig, said: "We are pleased that the company's acquisition and growth objectives are being accomplished, resulting in a significant gain in market share for calendar 1992. During fiscal 1993, our primary focus will be to further enhance customer service and to become more efficient in the distribution of product."
 Martini also commented: "A continuing decline in pharmaceutical gross profit margins due to reduced opportunities for investment buying and accelerated price competition has impacted earnings. We will work to offset some of the margin pressure by a reduction in the distribution, selling and administrative costs as a percent of net sales. We also are seeking to balance competitive pressures by signing long-term contracts with key customer groups."
 Bergen Brunswig Corp. is one of the nation's largest distributors of pharmaceutical and other health care products.
 BERGEN BRUNSWIG CORP.
 Summary of Consolidated Sales and Earnings
 (unaudited)
 (In thousands except share and per share amounts)
 First fiscal quarter
 Ended Nov. 30,
 1992 1991
 Net sales and other revenues $1,600,257 $1,149,221
 Costs and expenses:
 Cost of sales 1,496,643 1,077,857
 Distribution, selling, general
 and administrative expenses 78,376 60,233
 Total costs and expenses 1,575,019 1,138,090
 Operating earnings from
 continuing operations 25,238 11,131
 Net interest expense 5,021 1,005
 Earnings from continuing operations
 before taxes on income 20,217 10,126
 Taxes on income from continuing
 operations 8,289 3,491
 Earnings from continuing operations 11,928 6,635
 Earnings from discontinued
 operations, net of taxes on income --- 2,275
 Net earnings $11,928 $8,910
 Average number of common and common
 equivalent shares(a)
 Primary 35,957,574 40,092,223
 Fully diluted 43,725,065 47,859,714
 Earnings per share(a)
 Primary:
 Continuing operations $.33 $.17
 Discontinued operations --- .05
 Net earnings $.33 $.22
 Fully diluted(b):
 Continuing operations $.32 $.17
 Discontinued operations --- .05
 Net earnings $.32 $.22
 NOTE: Addback to net earnings for
 fully diluted earnings per share
 computation:
 LYONs interest, net of tax effect $2,110 $2,137
 (a) Earnings per common and common equivalent share are based on the weighted average number of shares of class A common stock outstanding during each period, the assumed conversion of the weighted average number of shares of class B common stock outstanding during each period and the assumed exercise of employees' stock options. Fully diluted earnings per share assume conversion of the LYONs due 2004 (zero coupon-subordinated) from the issue date of Nov. 16, 1989.
 (b) In the quarter ended Nov. 30, 1991, the computation of fully diluted earnings per share was anti-dilutive.
 -0- 12/16/92
 /CONTACT: Neil F. Dimick, executive VP and CFO of Bergen Brunswig, 714-385-4000/
 (BBC)


CO: Bergen Brunswig Corp. ST: California IN: MTC SU: ERN

KJ-LS -- LA011 -- 7568 12/16/92 09:03 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 16, 1992
Words:737
Previous Article:NATIONAL BEVERAGE CONTINUES TO SET RECORD EARNINGS
Next Article:FIDELITY NATIONAL FINANCIAL INC. DECLARES 3-FOR-2 STOCK SPLIT AND INCREASES CASH DIVIDEND BY 20 PERCENT
Topics:


Related Articles
NET EARNINGS AT BERGEN BRUNSWIG WILL BE LESS THAN EXPECTED; SHARE REPURCHASE PLAN EXTENDED
BERGEN BRUNSWIG REPORTS FIRST QUARTER RESULTS
BERGEN BRUNSWIG TO ACQUIRE PHARMACEUTICAL DISTRIBUTION BUSINESS FROM OWENS & MINOR
BERGEN BRUNSWIG SENDS LETTER TO DURR-FILLAUER MEDICAL BOARD
BERGEN BRUNSWIG ANNOUNCES MERGER AGREEMENT WITH DURR-FILLAUER
BERGEN BRUNSWIG REPORTS SECOND QUARTER AND FIRST HALF RESULTS
BERGEN BRUNSWIG REPORTS FIRST QUARTER RESULTS
Bergen Brunswig and IVAX Sign $3.2 Billion Definitive Merger Agreement
Bergen Brunswig Medical Corporation and Myriad Ultrasound Systems Announce Distribution Agreement.
HSCA Announces Development of a Primary Care Distribution Program With Bergen Brunswig Medical Corporation.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters